Please check your mail in a few minutes for our welcome email and Free Report. If you do not see an email from us, please check your spam folder and add to your approved/whitelist (or just click "not spam").

Email a Friend
Decrease text size Increase text size

Tamoxifen for Peyronie’s Disease Treatment

Tamoxifen for Peyronies Disease TreatmentTamoxifen for Peyronie’s Disease is an oral nonsteroidal anti-estrogen drug that is typically used to treat breast cancer patients. However, when given to men with Peyronie’s disease, some have reported an improvement in pain, size of plaque, and bend of the penis. These benefits may be associated with the ability of Tamoxifen for Peyronie’s Disease to promote the release of transforming growth factor-beta, which in turn can inhibit the inflammatory response and reduce production of cells (fibroblasts) involved in the creation of plaque. (Colletta 1990)

Studies of Tamoxifen for Peyronie’s Disease Treatment

Studies of tamoxifen in Peyronie’s patients have had conflicting results, however. In one study, for example, 36 men received 20 mg of tamoxifen twice a day for 3 months. Sixteen of 20 men said their pain improved, 11 of 31 had an improvement in penile curvature, and 12 of 35 had a reduction in plaque. (Ralph 1992) These promising results were not duplicated in another study of 25 men with Peyronie’s disease who received 20 mg of tamoxifen or placebo twice daily for three months. Evaluations done 4 months after treatment did not show any significant improvement in pain, penile curvature, or plaque size. (Teloken 1999-Tamoxifen for Peyronie’s Disease)

Dose and Side Effects of Tamoxifen for Peyronie’s Disease Treatment

The typical dose of tamoxifen for Peyronie’s disease is 20 mg twice a day for three months. Although men tolerate tamoxifen fairly well, side effects can include hair loss and gastrointestinal upset. Men should also know there is a risk for cancer, stroke, and blood clots in the lungs associated with the use of tamoxifen.


Colletta AA et al. Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. Br J Cancer 1990 Sep; 62(3): 405-9

Ralph DJ et al. The treatment of Peyronie’s disease with tamoxifen. Br J Urol Dec 1992; 70(6):648-51.

Teloken C et al. Tamoxifen versus placebo in the treatment of Peyronie’s disease. J Urol Dec 1999; 162(6):2003-5.

About Dr. Larry Lipshultz, M.D.

Dr. Lipshultz is Professor of Urology and Chief of the Division of Male Reproductive Medicine and Surgery at the Baylor College of Medicine in Houston, Texas . He is an internationally acclaimed fertility specialist and a pioneer in the field of urologic microsurgery, specializing in male infertility, erectile dysfunction, microsurgery, genetic causes of infertility, and age-related changes in male hormone levels (androgen replacement). He was a founder of the Society for the Study of Male Reproduction and is a Past President of the American Society for Reproductive Medicine. In addition, he has served on the FDA Advisory Committee for Reproductive Health Drugs. He was the first AUA Research scholar and was awarded the prestigious Hugh Hampton Young Award at the 2005 AUA Annual Meeting. More on Dr. Lipshultz

Site last updated 25 October, 2016



Likebox Slider Pro for WordPress